Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis

BMC Gastroenterology

Table 3 SUCRA score for clinical remission, clinical response, endoscopic improve, mucosal healing, adverse events, recurrence of ulcerative colitis, infections, adverse events resulting in treatment discontinuation, serious adverse events, serious infections in maintenance treatments

Clinical remission		Clinical response		Endoscopic improve		Mucosal Healing		Adverse events		Recurrence of ulcerative colitis		Infections		Adverse events resulting in treatment discontinuation		serious adverse events		serious infections
Vedoli	89.7	Inflix	75.8	Vedoli	92.6	Inflix	83.6	Vedoli	78.4	Guselku	92.9	Usteki	91.3	Usteki	80.4	Usteki	75.4	Usteki	67.6
Inflix	79.8	Usteki	66	Etrol	65.2	Etrol	69.1	Etrol	73.2	Usteki	89.3	Vedoli	8.8	Guselku	71	Inflix	66.2	Adal	63.1
Adal	72.7	Golimu	59.5	Usteki	34.7	Adal	64.5	Usteki	68.1	Etrol	62.9	Placebo	77.5	Vedoli	60.1	Adal	60.3	Placebo	53.7
Golimu	55.2	Adal	57.6	Placebo	7.5	Golimu	57.6	Placebo	54.2	Inflix	50.7	Guselku	64.8	Etrol	42.8	Placebo	58.1	Etrol	53.5
Etrol	48.1	Vedoli	53.3			Guselku	12.8	Adal	35.5	Vedoli	41.9	Adal	50.8	Adal	27.9	Vedoli	52.7	Inflix	49.2
Usteki	36.2	Guselku	42.8			Placebo	12.4	Golimu	35.2	Adal	39.5	Inflix	44.6	Inflix	59.2	Guselku	34.7	Guselku	34.9
Guselku	31.5	Etrol	39.9					Inflix	33.2	Golimu	16.7	Etrol	39.7	Placebo	29.7	Etrol	29.4	Golimu	28
Mesalazine	19.5	Placebo	34.9					Guselku	22.1	Placebo	6.1	Golimu	22.5	Golimu	29	Golimu	23.3
Placebo	17.2	Mesalazine	20.1

ISSN: 1471-230X